| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | $54.0M+51.5% | $35.6M-46.7% | $66.9M-48.6% | $130.1M+6.5% | $122.2M+179.1% | $43.8M |
| Marketable securities, short-term | $62.9M-53.7% | $135.9M-23.0% | $176.6M+271.8% | $47.5M-34.1% | $72.1M | — |
| Prepaid expenses and other current assets | $5.4M-20.2% | $6.7M+118.2% | $3.1M+13.5% | $2.7M-38.4% | $4.4M+714.7% | $543K |
| Total current assets | $122.3M-31.4% | $178.3M-27.7% | $246.6M+36.8% | $180.3M-9.2% | $198.7M+347.1% | $44.4M |
| Marketable securities, long-term | $0-100.0% | $60.0M-4.1% | $62.6M+295.0% | $15.8M-49.9% | $31.6M | — |
| Restricted cash | $231K-0.4% | $232K-0.4% | $233K | $0 | — | — |
| Other assets, long-term | $350K-28.0% | $486K-32.9% | $724K+379.5% | $151K+978.6% | $14K | — |
| Total assets | $122.8M-48.6% | $239.0M-22.9% | $310.1M+57.8% | $196.6M-14.6% | $230.3M+418.4% | $44.4M |
| Accounts payable | $554K-90.2% | $5.6M+309.6% | $1.4M-15.9% | $1.6M+50.7% | $1.1M+104.9% | $531K |
| Accrued clinical trial expenses | $10.6M-30.8% | $15.3M+249.8% | $4.4M+61.5% | $2.7M+1748.3% | $147K | — |
| Accrued expenses and other current liabilities | $10.1M+52.3% | $6.6M+2.6% | $6.4M+92.5% | $3.4M-14.4% | $3.9M+824.8% | $423K |
| Debt, short-term | $8.8M | $0 | — | — | — | — |
| Total current liabilities | $30.0M+8.7% | $27.6M+112.8% | $13.0M+66.0% | $7.8M+51.8% | $5.1M | — |
| Debt, long-term | $22.4M-23.9% | $29.4M-1.6% | $29.9M | $0 | — | — |
| Other liabilities, long-term | $0-100.0% | $150K-47.2% | $284K | — | — | — |
| Total liabilities | $52.4M-8.3% | $57.2M+32.5% | $43.2M+452.4% | $7.8M+51.8% | $5.1M-19.2% | $6.4M |
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding as of December 31, 2025 and 2024 | $0 | $0 | $0 | $0 | $0 | — |
| Common stock, $0.0001 par value; 300,000,000 shares authorized as of December 31, 2025 and 2024; 60,575,369 and 60,094,083 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $6K+0.0% | $6K+0.0% | $6K+50.0% | $4K+0.0% | $4K | — |
| Additional paid-in capital | $516.8M+1.9% | $507.0M+3.6% | $489.5M+36.0% | $359.9M+2.0% | $353.0M+4115.2% | $8.4M |
| Accumulated deficit | -$446.5M-37.3% | -$325.1M-45.9% | -$222.8M-30.7% | -$170.4M-33.6% | -$127.6M-373.1% | -$27.0M |
| Accumulated other comprehensive income (loss) | $83K+272.9% | -$48K-115.4% | $312K+141.5% | -$751K | — | — |
| Total stockholders’ equity | $70.4M-61.3% | $181.8M-31.9% | $267.0M+41.4% | $188.8M-16.2% | $225.2M+1311.2% | -$18.6M |
| Total liabilities and stockholders’ equity | $122.8M-48.6% | $239.0M-22.9% | $310.1M+57.8% | $196.6M-14.6% | $230.3M+418.4% | $44.4M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.